Publication | Closed Access

A randomised phase II study of oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cisplatin chemotherapy

Gastrointestinal OncologyMedicineFirst-line Gemcitabine/cisplatin ChemotherapyBiliary CancerCancer TreatmentOncologyRadiation OncologyCancer ResearchRadiologyHealth Sciences